Research map: Advances in the treatment of eosinophilic granulomatosis with polyangiitis
Back to the article
Papers in this map
- 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides · J. Charles Jennette · 2012 · 6684 citations · Cited by this paper
- Brepocitinib shows promise for dermatomyositis · 2026 · Related
- Nomenclature of Systemic Vasculitides · J. Charles Jennette · 1994 · 3861 citations · Cited by this paper
- The gut–joint axis in osteoarthritis · 2026 · Related
- Wegener Granulomatosis: An Analysis of 158 Patients · Gary Stuart Hoffman · 1992 · 2879 citations · Cited by this paper
- Anti-CD19 CAR T cell therapy promotes skin remodelling in systemic sclerosis · 2026 · Related
- Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis · John H. Stone · 2010 · 2776 citations · Cited by this paper
- Progress made and the road ahead for cancer screening in myositis · 2026 · Related
- Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma · Héctor Ortega · 2014 · 2341 citations · Cited by this paper
- 20 years of progress in the classification of immune-mediated diseases · 2026 · Related
- Wegener's Granulomatosis: Prospective Clinical and Therapeutic Experience With 85 Patients for 21 Years · Anthony S. Fauci · 1983 · 2014 citations · Cited by this paper
- The evolving comorbidity landscape of rheumatoid arthritis · 2026 · Related
- Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma · Pranabashis Haldar · 2009 · 1891 citations · Cited by this paper
- Decoding variants of uncertain significance in systemic autoinflammatory diseases · 2026 · Related
- Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis · Rachel Bronwen Jones · 2010 · 1760 citations · Cited by this paper
- Sex-dependent mechanisms in rheumatic diseases · 2026 · Related
- Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study · Julia Hippisley‐Cox · 2017 · 1760 citations · Cited by this paper
- Rethinking early-stage knee osteoarthritis beyond radiography · 2026 · Related
- Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials · Claus Bachert · 2019 · 1566 citations · Cited by this paper
- PD-1 agonism puts the brakes on pathogenic T cell responses in RA · 2026 · Related
- The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity · Toyohide Shinkawa · 2003 · 1422 citations · Cited by this paper
- Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial · J. Mark FitzGerald · 2016 · 1412 citations · Cited by this paper
- Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial · Eugene R. Bleecker · 2016 · 1411 citations · Cited by this paper
- Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial · Andrew Blauvelt · 2017 · 1269 citations · Cited by this paper
- Modification and validation of the Birmingham Vasculitis Activity Score (version 3) · Chetan B. Mukhtyar · 2008 · 1253 citations · Cited by this paper
- Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma · Klaus Friedrich Rabe · 2018 · 1195 citations · Cited by this paper
- Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials · Mario Castro · 2015 · 1191 citations · Cited by this paper
- Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria · Marcus Maurer · 2013 · 1108 citations · Cited by this paper
- Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis · Loı̈c Guillevin · 2014 · 1101 citations · Cited by this paper
- Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis · Michael E. Wechsler · 2017 · 1094 citations · Cited by this paper
- Churg-Strauss Syndrome Clinical Study and Long-Term Follow-Up of 96 Patients · Loı̈c Guillevin · 1999 · 1078 citations · Cited by this paper
- Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma · Parameswaran K. Nair · 2017 · 1059 citations · Cited by this paper
- Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma · Andrew N Menzies-Gow · 2021 · 1054 citations · Cited by this paper
- RETRACTED: Avacopan for the Treatment of ANCA-Associated Vasculitis · David R.W. Jayne · 2021 · 1018 citations · Cited by this paper
- Prognostic Factors in Polyarteritis Nodosa and Churg-Strauss Syndrome A Prospective Study in 342 Patients · Loı̈c Guillevin · 1996 · 1002 citations · Cited by this paper
- EULAR recommendations for the management of primary small and medium vessel vasculitis · Chetan B. Mukhtyar · 2008 · 995 citations · Cited by this paper
- The Five-Factor Score Revisited · Loı̈c Guillevin · 2010 · 956 citations · Cited by this paper
- International consensus statement on allergy and rhinology: rhinosinusitis 2021 · Richard R. Orlandi · 2020 · 950 citations · Cited by this paper
- Eosinophilic granulomatosis with polyangiitis (Churg‐Strauss): Clinical characteristics and long‐term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort · Cloé Comarmond · 2012 · 939 citations · Cited by this paper
Source: OpenAlex (CC0)